AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10711928
Drug: Subcutaneous Schwarz
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Schwarz vaccine
Trial: 10711928
Drug: Aerosol Schwarz
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol Schwarz vaccine
Trial: 9180629
Drug: Oral alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alcohol intake (1.0 g/kg body wt)
Trial: 27737361
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity laser therapy (Infrared laser, AsGaAI, wavelength of 790 nm, output power of 20 mW, fluence of 6 J/cm2)
Trial: 21729372
Drug: Energy-protein supplementation
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy-protein supplementation (one or six biscuits daily for 60 days)
Trial: 20134330
Drug: Lopinavir/ritonavir 800/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir 800/200 mg QD
Trial: 20134330
Drug: Lopinavir/ritonavir 400/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir 400/100 mg BID
Trial: 9555757
Drug: Montelukast (5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (5-mg chewable tablet) once daily at bedtime for 8 weeks
Trial: 9555757
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily at bedtime for 8 weeks
Trial: 28509904
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy emphasizing exercise during behavioral activation (CBT-E)
Trial: 28509904
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy with pleasurable low-energy activities (CBT-C)
Trial: 21167340
Drug: IRA infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IRA infusion of 10 million CD34(+) cells
Trial: 21167340
Drug: IRA infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IRA infusion of 5 million CD34(+) cells
Trial: 21167340
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no CD34(+) cell infusion)
Trial: 10828934
Drug: Multinutrient liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multinutrient liquid supplement
Trial: 1586984
Drug: Carmustine (BCNU)
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carmustine (BCNU) 200 mg/m2 alone
Trial: 1586984
Drug: Carmustine (BCNU)
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carmustine (BCNU) 200 mg/m2 in combination with recombinant human TNF-alpha (rhTNF alpha) 88 micrograms/m2
Trial: 1586984
Drug: Carmustine (BCNU)
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carmustine (BCNU) in combination with TNF
Trial: 29338751
Drug: Conventional didactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional didactic drug prevention course (2 sessions)
Trial: 22585378
Drug: 5-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day course of oral prednisolone
Trial: 18356189
Drug: Active-Passive Bilateral
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active-Passive Bilateral Therapy (APBT) for 10-15 min prior to self-directed motor practice
Trial: 18356189
Drug: Active-Passive Bilateral
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active-Passive Bilateral Therapy (APBT)
Trial: 17265483
Drug: Adalimumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (40 mg subcutaneously every other week)
Trial: 12487388
Drug: Saquinavir SGC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir SGC 1200 mg three-times daily plus two NRTIs (arm A)
Trial: 12487388
Drug: Saquinavir SGC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir SGC 1600 mg twice-daily plus two NRTIs (arm B)
Trial: 12487388
Drug: Saquinavir SGC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir SGC 1200 mg twice-daily and nelfinavir 1250 mg twice-daily plus a single NRTI (arm C)
Trial: 12487388
Drug: Saquinavir SGC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir SGC 1600 mg twice-daily (arm B)
Trial: 12487388
Drug: Saquinavir SGC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir SGC 1200 mg twice-daily and nelfinavir 1250 mg twice-daily (arm C)
Trial: 12487388
Drug: Saquinavir SGC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir SGC 1200 mg three-times daily (arm A)
Trial: 7783096
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR 240 mg once daily
Trial: 6085365
Drug: Nitrendipine (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (20-40 mg/day)
Trial: 6085365
Drug: Oxprenolol (160-320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol (160-320 mg/day)
Trial: 31381365
Drug: Competency-Based Approaches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Competency-Based Approaches to Community Health (COACH) intervention, consisting of 15 weekly, 90-minute sessions followed by 3 months of twice-monthly health coaching calls.
Trial: 31381365
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving a twice-monthly school readiness curriculum for 3 months.
Trial: 25252515
Drug: Structured behavioural
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured behavioural management and pharmacological treatment
Trial: 22372512
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg molindone (5 mg if weight <30 kg)
Trial: 22372512
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg molindone (10 mg if weight <30 kg)
Trial: 22372512
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg molindone (15 mg if weight <30 kg)
Trial: 22372512
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg molindone (20 mg if weight <30 kg)
Trial: 18271234
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (Haloperidol orally)
Trial: 16898430
Drug: Experimental mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental mouthwash formulation
Trial: 15255163
Drug: Irinotecan, cisplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan, cisplatin, and etoposide (IPE) administered every 4 weeks (arm B)
Trial: 3158320
Drug: Triphasic preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic preparation containing levonorgestrel + ethinylestradiol
Trial: 31859087
Drug: Collagen-based supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen-based supplement (1000 kcal)
Trial: 28106331
Drug: High-dose antivenom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose antivenom (20 vials)
Trial: 28106331
Drug: Low-dose antivenom
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose antivenom (10 vials) plus 4 U of fresh frozen plasma (FFP)
Trial: 25929712
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard therapies)
Trial: 18645050
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg slow-release, once daily)
Trial: 17074656
Drug: FEC50 (fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC50 (fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2), cyclophosphamide 500 mg/m(2), 6 cycles every 21 days)
Trial: 17074656
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no systemic treatment)
Trial: 10993030
Drug: 17beta-estradiol 1
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17beta-estradiol 1 mg
Trial: 10993030
Drug: 17beta-estradiol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17beta-estradiol 0.5 mg
Trial: 3909321
Drug: Intravenous aztreonam
RxNorm normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous aztreonam (1-2 g every 8 hr)
Trial: 3909321
Drug: Intravenous tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous tobramycin (3-5 mg/kg per day)
Trial: 26922019
Drug: Lung protective
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung protective ventilation (VT of 6 mL/kg + RMs + PEEP: 5 cmH(2)O (PBW) and RR of 12‐18 /min)
Trial: 26922019
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (VT of 10 mL/kg (PBW) and RR of 10‐12 /min)
Trial: 24346821
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) 1000 mg
Trial: 11290878
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) 400 mg
Trial: 14975052
Drug: T‐piece mode
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T‐piece mode (4 l/min oxygen via a T‐piece for 2 hours)
Trial: 8214998
Drug: Weight-based heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based heparin nomogram (starting dose, 80 units/kg body weight bolus, 18 units/kg per hour infusion)
Trial: 24210549
Drug: Apparent treatment-resistant
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apparent treatment-resistant hypertension
Trial: 22440192
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 8 mg and amlodipine besilate 5 mg (CC/AML 8/5 mg)
Trial: 22440192
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 8 mg (CC 8 mg)
Trial: 22440192
Drug: Amlodipine besilate
RxNorm normalized name: Amlodipine besilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine besilate 5 mg (AML 5 mg)
Trial: 20632489
Drug: Routine methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine methods and topical oxygen therapy (Group B)
Trial: 20632489
Drug: Routine methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine methods and bFGF therapy (Group C)
Trial: 20632489
Drug: Routine methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine methods and bFGF/topical oxygen therapy (Group D)
Trial: 17717526
Drug: Alfuzosin 10
RxNorm normalized name: Alfuzosin 10mg Oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 10 mg once daily (q.d.)
Trial: 16297757
Drug: Butorphanol (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol (0.02 mg/kg)
Trial: 11905429
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin (10 units)
Trial: 11905429
Drug: Intramuscular syntometrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular syntometrine (1 ml)
Trial: 10707131
Drug: 0.25 ml
RxNorm normalized name: mineral oil 0.25 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 ml of Mydricaine No. 1
Trial: 8944370
Drug: Mesalazine 500
RxNorm normalized name: mesalazine 500 Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine 500 mg thrice daily for 7 days
Trial: 8944370
Drug: Olsalazine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olsalazine 500 mg twice daily for 7 days
Trial: 31961224
Drug: Bevacizumab (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (2.5 mg) - three intravitreal injections at monthly intervals
Trial: 31961224
Drug: Triamcinolone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinolone (8 mg) - single injection followed by two sham interventions at monthly intervals
Trial: 22397239
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ramipril and valsartan (N = 26)
Trial: 22397239
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (ramipril + valsartan)
Trial: 22397239
Drug: Monotherapy (ramipril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (ramipril or valsartan)
Trial: 17509426
Drug: N-acetylcysteine (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (twice per day dosing regimen: one dose before and three doses after contrast media exposure)
Trial: 17509426
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice per day dosing regimen: one dose before and three doses after contrast media exposure)
Trial: 14715839
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg melatonin daily for 4 weeks
Trial: 14715839
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg melatonin daily for 4 weeks (second study)
Trial: 9368234
Drug: intensive oral
RxNorm normalized name: Uricalm Intensive Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intensive oral + i.v. magnesium supplementation
Trial: 1609935
Drug: Bolus plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus plus infusion (4 ml incremental bolus with 15 minute lockout, plus a 4 ml per hour infusion of 0.125% bupivacaine plus fentanyl 3 mcg per ml)
Trial: 1609935
Drug: Bolus only
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus only (4 ml incremental bolus with 15 minute lockout of 0.125% bupivacaine plus fentanyl 3 mcg per ml)
Trial: 3594511
Drug: Clopamide monotherapy
RxNorm normalized name: clopamide
DrugBank: Clopamide (DB13792)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopamide monotherapy
Trial: 363480
Drug: Pindolol monotherapy
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pindolol monotherapy
Trial: 3594511
Drug: Combined pindolol-clopamide
RxNorm normalized name: clopamide / pindolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined pindolol-clopamide therapy
Trial: 26043562
Drug: Wuling Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wuling Capsule (0.33 g/capsule, 3 times per day) + Pinaverium Bromide (50 mg/tablet, 3 times per day)
Trial: 26043562
Drug: Pinaverium Bromide
RxNorm normalized name: pinaverium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinaverium Bromide (50 mg/tablet, 3 times per day)
Trial: 26043562
Drug: Wuling Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wuling Capsule + Pinaverium Bromide
Trial: 23829154
Drug: Caffeine gum
RxNorm normalized name: caffeine Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine gum (100 mg)
Trial: 14623808
Drug: Adenosine (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (0.125 mg/min)
Trial: 14623808
Drug: Adenosine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (0.5 mg/min)
Trial: 14623808
Drug: Dipyridamole (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (loading dose, 0.142 mg/kg per min for 5 minutes followed by 0.004 mg/kg per min)
Trial: 10632647
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg o.d. for the first 6 days (PAAz group; n=55)
Trial: 10632647
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg b.d. for the first 7 days (PAC group; n=55)
Trial: 3987798
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of cefuroxime (250 mg) in patients with peritonitis
Trial: 3987798
Drug: Intraperitoneal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal administration of cefuroxime (250 mg) in patients with peritonitis
Trial: 3987798
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of cefuroxime (250 mg) in uninfected patients
Trial: 3987798
Drug: Intraperitoneal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal administration of cefuroxime (250 mg) in uninfected patients
Trial: 29330176
Drug: Guided physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided physical exercise and dietary therapy programme (PED‐t)
Trial: 25377395
Drug: Morphine and
RxNorm normalized name: morphine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine and 0.15 mg/kg ketamine (group 1)
Trial: 25377395
Drug: Morphine and
RxNorm normalized name: morphine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine and 0.3 mg/kg ketamine (group 2)
Trial: 25377395
Drug: Morphine and
RxNorm normalized name: morphine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine and normal saline placebo (standard care group)
Trial: 23718080
Drug: 2% procaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% procaine solution administered via electrophoresis and mesotherapy
Trial: 23718080
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via galvanization and mesotherapy
Trial: 18226669
Drug: Monophasic combination
RxNorm normalized name: Monobasic Potassium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monophasic combination oral contraceptive (COC)
Trial: 9180855
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 30 mg/day for 5 years
Trial: 1286499
Drug: Flumazenil (0.89
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.89 mg IV, range: 0.4 mg to 1 mg)
Trial: 3812947
Drug: Intramuscular nalbuphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular nalbuphine 20 mg
Trial: 26446253
Drug: Zolpidem 10
RxNorm normalized name: zolpidem 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 10 mg nightly
Trial: 25703411
Drug: NPWT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPWT with sNAG in patients treated with antiplatelet drugs
Trial: 23735352
Drug: N-acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (600 mg administered intravenously twice)
Trial: 23735352
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (500 mg administered intravenously twice)
Trial: 8712143
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 to 10 mg every morning)
Trial: 8712143
Drug: Diltiazem-sustained release
RxNorm normalized name: diltiazem Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem-sustained release (90 to 180 mg twice daily)
Trial: 1940058
Drug: AZT 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZT 0.5 g/day p.o.
Trial: 1940058
Drug: AZT 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZT 0.5 g/day p.o. plus IVIG 0.4 g/kg for three consecutive days, followed by 0.6 g/kg every fourth week
Trial: 1940058
Drug: AZT 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZT 0.5 g/day p.o. and IVIG
Trial: 1940058
Drug: AZT 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZT 0.5 g/day p.o. plus IVIG
Trial: 8925582
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo capsules
Trial: 9205768
Drug: Ebrotidine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebrotidine 400 mg and ranitidine 300 mg combined with amoxicillin 750 mg and metronidazole 500 mg for 14 days
Trial: 9205768
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving the same treatment